Health Technology

MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Surgery, Hospitals, FDA, Health Technology, Hardware, Robotics, Health, Oncology, Freedom, Surgeon, Classification, Lymphedema, Filtration, Physician, Patient, Hospital, European, Platform supply vessel, Tremor, Blood, Wrist, Hand, Microsurgery, Food, Medicine, Dentistry

The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.

Key Points: 
  • The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.
  • “With the authorization from the FDA, our technology will expand its reach to pioneering hospitals in the U.S.
  • The Symani Surgical System provides advanced solutions for a range of open surgeries, including post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer, and lymphatic system repair.
  • MMI plans to immediately launch the technology in the U.S.
    To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com .

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

Retrieved on: 
Tuesday, April 9, 2024
Physical Therapy, Technology, Managed Care, Health, Optical, Health Technology, Medical Devices, Photography, Software, Artificial Intelligence, Telemedicine, Virtual Medicine, Research, Diagnosis, Glaucoma, CE, Patient, Hospital, ARVO, IPredict, Paratriathlon, TGA, AMD, Diabetic retinopathy

The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.

Key Points: 
  • The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.
  • The entire test which includes color retinal imaging and the automated AI-based glaucoma report generation can easily and reliably be completed within 5 minutes.
  • Glaucoma detection offers an overall accuracy of 94.3% for identifying an individual with glaucoma.
  • iPredict’s glaucoma detection model can be used as follows:
    iPredict-glaucoma report will produce which will indicate referable (i.e., early to severe glaucoma) or non-referable glaucoma (not glaucoma).

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024
Health, Manufacturing, Health Technology, Clinical Trials, Other Manufacturing, Pharmaceutical, Biotechnology, CDMO, Growth, Capsule, Risk, Rheometer, Acquisition, FT4, Senior, Investment, Clinical trial, API, Korsch, Fine chemical

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

Retrieved on: 
Monday, April 8, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, Health Technology, Other Science, Research, Data Analytics, Software, Science, Cloud, CRM, Organization, Partnership, OCE, SVP, Sale, AI, Patient safety, HCP, IQV, Fine chemical

IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
  • Building on the IQVIA Orchestrated Customer Engagement ( OCE ) platform, launched in 2017, the partnership will apply innovations from IQVIA OCE with Salesforce’s Life Sciences Cloud to provide customers with a new single, end-to-end engagement platform.
  • As part of the expanded partnership, IQVIA will license the OCE CRM related software to Salesforce, and the parties will collaborate to accelerate development of Life Sciences Cloud for customer engagement, expected to be available in 2025*.
  • “Our collaboration with IQVIA marks a pivotal moment for Salesforce Life Sciences Cloud innovation.

Model N to be Acquired by Vista Equity Partners For $1.25 Billion

Retrieved on: 
Monday, April 8, 2024
Professional Services, Health, Data Analytics, Technology, Health Technology, Other Technology, Pharmaceutical, Culture, Growth, ARR, Model N, Sale, LLP, Senior, Medtech, Vista Equity Partners, Model, Jefferies Group, Kirkland & Ellis, HSR

Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.

Key Points: 
  • Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.
  • Under the terms of the agreement, Vista will acquire all the outstanding shares of Model N common stock for $30.00 per share in an all-cash transaction valued at approximately $1.25 billion.
  • Upon completion of the transaction, Model N will become a privately held company and shares of Model N common stock will no longer be listed on any public market.
  • Jefferies LLC is serving as exclusive financial advisor and provided a fairness opinion to Model N, and Fenwick & West LLP is serving as legal counsel.

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Health Technology, Nanotechnology, Other Health, Biotechnology, Hardware, Managed Care, Health, Data Management, Moses Austin, Conditional sentence, University, Professor, IL-6, Perspiration, Patient, Inflammation, Biomarker, Research, AI, Doctor of Philosophy, Senior, IBD, Translation, Management, C-reactive protein, Inflammatory bowel disease, Inflammatory Bowel Diseases, Trial of the century, CRP, Pharmaceutical industry

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

Data I/O Announces Major Milestone with 500th PSV System Sale Ahead of IPC APEX Expo

Retrieved on: 
Monday, April 8, 2024
Automotive Manufacturing, Semiconductor, Security, IOT (Internet of Things), Manufacturing, Vehicle Technology, Automotive, Other Technology, Medical Devices, Internet, Consumer Electronics, Technology, Mobile, Wireless, Other Manufacturing, Health, General Automotive, Engineering, Health Technology, UFS, ICS, Data I/O, Connex, Original equipment manufacturer, Partnership, Internet of things, 500th, Electronics, Sale, PSV, GitHub, Graph, Data-rate units, GraphQL, Family, IPC, Silicon, MQTT, Anaheim Convention Center, Video game

Data I/O Corporation (NASDAQ: DAIO), the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, announced the Company has achieved a major milestone with the sale of the 500th PSV automated programming system.

Key Points: 
  • Data I/O Corporation (NASDAQ: DAIO), the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, announced the Company has achieved a major milestone with the sale of the 500th PSV automated programming system.
  • Demonstrations of the PSV family will be available in Data I/O’s booth #3107 at the upcoming IPC APEX Expo in Anaheim, California from April 9th – 11th at the Anaheim Convention Center.
  • The PSV family helps them address these challenges,” said Anthony Ambrose, President and CEO at Data I/O Corporation.
  • Customers attending the IPC APEX Expo in Anaheim, California can visit Data I/O’s booth in booth #3107 to see these live product demonstrations.

Humana Focuses on Reducing Health Disparities and Making Healthy Living Possible for All

Retrieved on: 
Monday, April 8, 2024
Managed Care, General Health, Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Consumer, Health, Health Technology, Other Philanthropy, Health Insurance, Sustainability, Environmental, Social and Governance (ESG), Other Consumer, Environment, Insurance, Pharmaceutical, Seniors, Science Based Targets initiative, Growth, Learning, Biophysical environment, Inc., Physician, GHG, ESG, Star, Patient, Education, Pharmacy, Science, Small business, Impact, Social, Patient satisfaction, Investment, Housing, Medicaid, Population health, Safety, Multimedia, Medicare, CMS, Medicare Advantage, Risk management

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    “We’re committed to making the healthcare system more equitable, affordable and easier to navigate,” said Bruce Broussard, Humana’s Chief Executive Officer.
  • 1.8 million Humana members across Medicare Advantage, Medicaid and commercial plans received screening for social health needs, helping to support their basic needs and address their health holistically.
  • CenterWell’s senior primary care, home health and pharmacy services provided more patients with integrated and differentiated experiences that improve health outcomes.
  • To learn more about Humana’s impact and continuing work to make it easier for people to achieve their best health, read the full 2023 Humana Impact Report .

Align Technology Launches Integrated Consumer Campaign and #Invisisforkids to Drive Awareness of How the Invisalign® Palatal Expander System Is a Better Option for Expanding a Child’s Narrow Palate to Make Room for Adult Teeth

Retrieved on: 
Monday, April 8, 2024
Health, Parenting, Medical Devices, Children, Family, Health Technology, Consumer, Dental, Align Technology, Patient, Social media, Child, Anxiety, Trial of the century, Pain, Multimedia, Oral hygiene, FDA, Parent, IPE

The Invisalign Palatal Expander System is the only FDA-cleared, removable palatal expander that’s just as effective as traditional fixed expanders.

Key Points: 
  • The Invisalign Palatal Expander System is the only FDA-cleared, removable palatal expander that’s just as effective as traditional fixed expanders.
  • 3 With no metal or wires in the way, your child can easily pop out the Invisalign Palatal Expander to brush and floss as usual.
  • Based on data from a multi-site US IDE clinical study (n=29 subjects, ages 7-10 years) of expansion treatment with Invisalign® Palatal Expanders.
  • Data on file at Align Technology, as of September 5, 2023.

SHL Telemedicine’s SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

Retrieved on: 
Monday, April 8, 2024
Cardiology, Telemedicine, Virtual Medicine, Defense, Military, General Health, Health, Medical Devices, Health Technology, Mojave Desert, Trauma, Telehealth, Military medicine, SHL, Fortification, Nursing, Physician, ECG

One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.

Key Points: 
  • One key event during the experiment was a comprehensive multi-day army medical experiment held at Fort Irwin’s National Training Center in the Mojave Desert amidst the challenging terrains of California’s Tiefort Mountains.
  • PC-C4, a joint, multinational experiment hosted by the U.S. Army across multiple locations in February and March allowed military medicine to explore and integrate the latest technological innovations in a field environment.
  • SmartHeart’s inclusion in this prestigious experiment underscores the growing recognition of SHL’s portable ECG technology as a game-changer in the fast-paced and demanding field of military healthcare.
  • It addresses a crucial need in the continuum of military medical care from initial non-battle evaluation to trauma response, to advanced interventions for intensive and continual care.